Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting injectable risperidone.

Megan J Ehret1, Matthew A Fuller

  • 1Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Rd., Brecksville, OH 44141-3204, USA.

The Annals of Pharmacotherapy
|November 4, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Xanomeline-Trospium for the Treatment of Schizophrenia.

Focus (American Psychiatric Publishing)·2026
Same author

Switching Between Long-Acting Injectable Antipsychotic Medications.

Focus (American Psychiatric Publishing)·2026
Same author

Pharmacological and Somatic Treatments for First-Episode Psychosis and Schizophrenia: Synopsis of the US Department of Veterans Affairs and US Department of Defense Clinical Practice Guidelines.

Schizophrenia bulletin·2025
Same author

A Randomized Controlled Trial of an Extension for Community Healthcare Outcomes (ECHO) Tele-mentoring Program to Increase Clozapine Utilization.

Schizophrenia bulletin·2025
Same author

Synopsis of the 2023 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline for the Management of Bipolar Disorder.

The Journal of clinical psychiatry·2025
Same author

Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.

The American journal of psychiatry·2025
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
See all related articles

Long-acting risperidone, an injectable antipsychotic, is effective and safe for schizophrenia treatment. This medication offers a new option for managing schizophrenia symptoms with a similar side effect profile to oral forms.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Schizophrenia requires effective and sustained treatment options.
  • Long-acting injectable antipsychotics offer potential benefits for treatment adherence.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of long-acting (LA) risperidone.
  • To evaluate risperidone LA as a treatment for schizophrenia.

Main Methods:

  • Literature search of PubMed (1965-July 2004) and scientific posters.
  • Inclusion of all published information providing a comprehensive description of risperidone LA.

Main Results:

  • Risperidone LA is the first long-acting, injectable atypical antipsychotic, dosed every two weeks.

Related Experiment Videos

  • It demonstrated superiority over placebo in reducing schizophrenia symptoms in short-term studies.
  • Stable patients could be switched to risperidone LA from oral or other injectable antipsychotics.

    • Conclusions:

    • Long-acting risperidone is an efficacious and safe treatment for schizophrenia.
    • It represents a viable therapeutic option for schizophrenia management.